TAO, WENG,REIN, DAVID H.,DEAN, BRENDA, J.,STABILA, PAUL F.,GODDARD, MOSES B. I.
申请号：
CA2365532
公开号：
CA2365532C
申请日:
2000.04.06
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
ARPE-19 cells were evaluated as a platform cell line for encapsulated andunencapsulated cell-based delivery technology. ARPE-19 cells were found to behardy (the cell line is viable under stringent conditions, such as in centralnervous system or intra-ocular environment)； can be genetically modified tosecrete the protein of choice； has a long life span； is of human origin； hasgoodin vivo device viability； delivers efficacious quantity of growth factor；triggers no or low level host immune reaction, and is non-tumorigenic.
